Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}} Now: 1770452475152 Cache Key: cqdTagPageBySlug:diffuse-large-b-cell-lymphoma fetchCache[cqdTagPageBySlug:diffuse-large-b-cell-lymphoma].expirationTime: falsey fetchCache[cqdTagPageBySlug:diffuse-large-b-cell-lymphoma]. seconds remaining: falsey All fetchCache expiration times: -- Key: cqdNotFoundPage, seconds remaining: 5517 -- Key: cqdTagPageBySlug:hearing-devices, seconds remaining: 5508 -- Key: cqdTagPageBySlug:aua19, seconds remaining: 5517 -- Key: cqdPostsByTag:cqd-migrated-tag-18443,1,10, seconds remaining: 5560 -- Key: cqdPostsByTag:cqd-migrated-tag-20506,1,10, seconds remaining: 5567 -- Key: cqdTagPageBySlug:accountability, seconds remaining: 5745 -- Key: cqdPostsByTag:cqd-migrated-tag-19756,1,10, seconds remaining: 5792 -- Key: cqdTagPageBySlug:refractive-surgery, seconds remaining: 5966 -- Key: cqdPostsByTag:cqd-migrated-tag-379,1,10, seconds remaining: 6022 -- Key: cqdTagPageBySlug:echocardiogram, seconds remaining: 7212 -- Key: cqdPostsByTag:cqd-migrated-tag-1788,1,10, seconds remaining: 7286 -- Key: cqdTagPageBySlug:screenings, seconds remaining: 7547 -- Key: cqdPostsByTag:cqd-migrated-tag-3843,1,10, seconds remaining: 7593 -- Key: cqdTagPageBySlug:okr, seconds remaining: 8191 -- Key: cqdPostsByTag:cqd-migrated-tag-23017,1,10, seconds remaining: 8238 -- Key: cqdTagPageBySlug:infants, seconds remaining: 8416 -- Key: cqdPostsByTag:cqd-migrated-tag-18417,1,10, seconds remaining: 8460 -- Key: cqdTagPageBySlug:trem2, seconds remaining: 9364 -- Key: cqdPostsByTag:cqd-migrated-tag-20829,1,10, seconds remaining: 9438 conditions: -- false, -- NA, -- NA, -- NA -- false Cache miss for key cqdTagPageBySlug:diffuse-large-b-cell-lymphoma - retrieving from Sanity CCCache.dataFetchCount: 974 Cache cleanup seconds remaining: 25508
Advertisement
Advertisement
Tag: diffuse large b-cell lymphoma
Age alone should not rule out patients from potentially curative treatment
Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
CAR T-cell therapy, bispecifics and antibody drug conjugates have changed disease management
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Cleveland Clinic Cancer Institute takes multi-faceted approach to ensuring clinical trials representation
Dispelling myths and sharing practical experiences
Distinct molecular features found in five subtypes of disease
Patients who relapse early after first-line chemotherapy are often, but not always, refractory to second-line chemotherapy
A New Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma
Improving safety, efficacy and access for emerging therapies
Rendered: Sat Feb 07 2026 08:21:15 GMT+0000 (Coordinated Universal Time)
9500 Euclid Avenue, Cleveland, Ohio 44195 |
800.223.2273 | ©
2026 Cleveland Clinic. All Rights Reserved.
Search
